Qyuns Therapeutics Co. Ltd. (中国)

The company was establish in Taizhou, Jiangsu Province, People's Taizhou, Republic of China on 16 June 2015.The company listing at Hong Kong stock exchange on 20 March 2024. The company are a clinical-stage biotech company exclusively focused on biologic therapies for autoimmune and allergic diseases. Leveraging the company integrated R D and manufacturing platform, have built a broad pipeline that covers the four major disease areas in the field, including skin, rheumatic, respiratory and digestive diseases.
History Company
Year Milestone event
2015 The Company was established in Taizhou, the PRC in June 2015.
2016 The company completed the Series A Financing and raised RMB120 million in March 2016.
2018 The company received IND approval of QX001S from the NMPA for the treatment of moderate-to-severe plaque Ps in China in January 2018.
2019 The company received IND approval of QX002N from the NMPA for the treatment of active AS in adults in China in April 2019.
2020 The company completed the Phase I clinical trial of QX001S for the treatment of Ps in China in May 2020.
2021 The company completed the Series B++ Financing and raised RMB300 million in April 2021.
2022 The company completed the Series C Financing and raised RMB227.5 million in March 2022.
2023 The completed the Phase Ia clinical trial of QX005N in healthy subjects in China in January 2023.
2024 The company entered into a technology transfer agreement in January 2024 with Joincare Pharmaceutical Group Industry Co., Ltd. (“Joincare”), to grant Joincare an exclusive license to develop, manufacture and commercialize QX008N in mainland China, Hong Kong and Macau.
The company product QX005N received the breakthrough therapy designation for the treatment of PN from the CDE in January 2024.